Podcasts about Efficacy

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Tsen Vei Lim speaks to Dr Joshua Garfield, a research fellow at Monash University and Turning Point, Australia. The interview covers Joshua's research article on the efficacy of a personalised alcohol ‘approach bias modification' smartphone app in people accessing outpatient treatment for alcohol use disorders.What is ‘approach bias modification' [01:51]The smartphone app and how it works [04:30]The recruitment process of the randomised controlled trial [07:20]The key findings of the study [09:20]How did the participants of the study feel about using the app? [10:37]The implications of the study for practice [12:33]The next steps for this app and using the app in different populations [13:54]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK).About Joshua Garfield: Joshua completed a Bachelor of Science with Honours in Psychology at the University of Tasmania in 2002, and then a PhD in Behavioural Neuroscience at the University of New South Wales in 2008, where he studied animal learning theory. Following a brief post-PhD role in depression research, he moved to Melbourne to work for Monash University at Turning Point, an addiction treatment, research, and workforce training institute. Since 2015, he has managed Turning Point's cognitive bias modification research program, led by Professor Victoria Manning.Original article: Efficacy of a personalised alcohol approach bias modification smartphone app in people accessing outpatient alcohol use disorder treatment: A randomised controlled trial https://doi.org/10.1111/add.70184The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Featuring an interview with Dr Erika Hamilton, including the following topics: General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00) Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11) Mechanisms of resistance to endocrine therapy (10:08) Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26) Other applications for PROTACs (24:24) Emerging data from the Phase III evERA trial (27:38) Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51) CME information and select publications

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Filip Rob, the Department of head of the Dermatovenereology at the Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic, as they discuss his recent paper ‘Efficacy, safety, and drug survival during the first year of biologic therapy for psoriasis in elderly versus younger patients'.

Escuchamos en redes sociales que suplementar omegas sería lo ideal para todos, vamos al a farmacia y encontramos una gran variedad que nos complica la decisión de cuál comprar. En este episodio te explico qué es este tipo de grasa, qué hace por tu salud y qué deberías revisar en la etiqueta a la hora de elegir. Suscríbete para más episodios donde traducimos la nutrición científica a tu vida real. Déjame en comentarios tus dudas o experiencias con el inositol. ¡Escríbenos! L.N Carla Paola AM ⚕ Envíame un WhatsApp 55 6325 6115. Búscame en Facebook, X e Instagram como @Nut.CarlaPaola #NutrieatContigo --------- Referencias: Bhatt, D. L., Steg, G. P., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., … & Clearfield, M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine, 380(17), 1678-1695. Ovid+1 Coelho, J. C., Pontes, F. R., Mila, A. L. A., & Machado, S. (2022). Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis. [Journal name], [volume], [pages]. PubMed Hu, Y., You, Z., & Zhu, X. (2021). Effect of long-term marine ω-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: A systematic review and meta-analysis. [Journal name], [volume], [pages]. PubMed Kou, S., & Hasan, A. (2021). Association between omega-3 fatty acid treatment and atrial fibrillation in cardiovascular outcome trials: A systematic review and meta-analysis. [Journal name], [volume], [pages].

European Study of Prostate Cancer Screening — 23-Year Follow-upAssociation Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering TherapyFurther Reading* Effects of intensive blood-pressure control in type 2 diabetes mellitus* A Randomized Trial of Intensive versus Standard Blood-Pressure ControlSensible Medicine is 100% reader-supported. If you appreciate our work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: This episode was supported by Greater Manchester NHS who received support from Boehringer.  You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis.  Show citations:  Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Show SummaryNatalie Elliott Handy, a caregiver for her husband and mother and co-host of the Confessions of a Reluctant Caregiver Podcast. During our conversation, we share the commitment that she and her sister have to highlighting and supporting military connected caregivers. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestNatalie is someone who genuinely loves people. She has a natural passion for meeting new faces, staying closely connected with family, friends, and colleagues, and, most of all, helping others. Anyone who knows her will readily say, “Natalie doesn't know a stranger.” It's simply who she has always been.Raised in her family's hardware store, Natalie learned early how to engage customers — and how to count change — by talking to everyone who walked through the door. At church, she was the first to volunteer to sing, recite Bible verses in “big church,” and attend every youth activity, especially lock-ins. In school, her teachers often placed her in the front row to help minimize “distractions,” because she was, without a doubt, a social butterfly.Those gifts — her ability to connect, her quick wit, and her desire to support others — naturally led her into leadership roles throughout her career in the mental health field. She married young at 21 and, many years later, again at 39. She often describes her first marriage as a light-hearted “practice run” with someone kind, but not Jason, the partner she shares her life with today.From the outside, Natalie's life looked picture-perfect: a fulfilling job, a loving husband, a close-knit support system, and of course, her beloved dogs. But behind the scenes, she was burning the candle at both ends — working 12-hour days, six days a week, answering every request with, “No problem. Happy to help.”Everything shifted when Jason was diagnosed with cancer in March 2022. In the midst of that crisis, Natalie confronted the truth that she couldn't keep living at that pace. During those darkest moments, she reconnected with her faith and, through that, rediscovered her true self. She learned to acknowledge her imperfections and, more importantly, to love herself fully — flaws and all.Today, Natalie has reordered her life with clear priorities: God, herself, Jason, family and friends, and then work. She says “no” far more often, seeks silver linings in difficult moments, and is grateful for the journey that led her to live God's plan instead of her own. She embraces the mantra of being “perfectly imperfect.”Her mission is simple: to share stories and experiences that inspire, uplift, and — whenever possible — spark a little laughter. She strives to encourage others to be true to themselves while supporting the people they love. And along the way, she fully intends to keep making new friends.Links Mentioned During the EpisodeConfessions of a Reluctant Caregiver Website2024 Heroes Caring for Heroes series2023 Heroes Caring for Heroes seriesPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.  Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation.   In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape   Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48]   Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui

Dans cet épisode, je plonge au cœur des diagnostics et étiquettes les plus souvent utilisés pour éviter de bouger avec Maryann Kerry-Dupuis.Cet épisode n'a rien de culpabilisant : c'est une invitation à comprendre ton corps autrement, à sortir du mode « je ne peux pas » et à reconnecter avec ta capacité naturelle à bouger.Tu vas découvrir :Les “diagnostics” les plus populaires qui freinent les gens Les derniers résultats de recherche sur la fibromyalgiePourquoi ils deviennent si souvent des excuses involontairesCe que la science dit réellement sur le mouvement et la douleurComment bouger intelligemment, même avec des limitationsRéférences :1) Di Tella & Castelli, Trauma and Fibromyalgia: Is there an association and what does it mean?, 2025, PubMed ID 406846692) López-Martínez et al., The role of lifetime stressors in adult fibromyalgia, 2021, PubMed ID 336023733) González et al., Prevalence and characterization of psychological trauma in patients with fibromyalgia, 2022, PubMed ID 365047594) Kosek et al., Central Processes Underlying Fibromyalgia, European Medical Journal, 20185) American College of Rheumatology, Guidelines 20236) www.health.harvard.edu : strength-training-builds-more-than-muscles7) A Ram Hong et Sang Wan Kim : Effects of resistance exerciceon bone health, 20188) www150.statcan.gc.ca9) www.jrheum.org10) www.tandfonline.com : Efficacy of strengthening exercices for osteoarthristis11) https://journals.lww.com/pain/fulltext/2019/11000/altered_microbiome_composition_in_individuals_with.18.aspx12) https://journals.lww.com/pain/abstract/2023/02000/altered_serum_bile_acid_profile_in_fibromyalgia_is.9.aspx_________________________________Vous souhaitez avoir un coaching privé avec Marie-Claude ?Cliquez sur le lien suivant : https://stan.store/ellethrivecoaching Vous pouvez rejoindre notre invité sur Instagram : Maryann Kerr-Dupuis @thisismaryann_NB:Nous tenons à souligner que nous ne sommes pas des professionnels de la santé. Notre objectif est d'informer et de vulgariser des informations pour le grand public. Bien que nous nous efforcions de fournir des contenus précis et fiables, il est important de consulter des experts qualifiés pour des conseils médicaux ou psychologiques personnalisés. Notre intention est de partager des connaissances dans le but de sensibiliser et d'éduquer, mais nous encourageons toujours nos auditeurs à rechercher des sources spécialisées et à prendre des décisions éclairées en matière de santé. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Struggle with your head held high!Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter:  @elliottspeaksInstagram: @elliottspeaks Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter: @elliottspeaksInstagram: @elliottspeaks

In episode #203 we dig into various recovery modalities, evaluating their efficacy and actual relevance for improving recovery times. Some of the modalities covered in this episode  are infrared and traditional saunas, cold water immersion, hot baths, “active recovery”, yoga classes, compression therapy, manual therapy, sleep monitoring devices, and supplements. We highlight the importance of understanding which modalities are truly beneficial and which are likely overhyped.Timestamps:00:00 Introduction to Recovery Modalities12:21 The Importance of Sleep and Nutrition15:17 Sauna: Infrared vs Traditional23:21 Cold Water Immersion and Ice Baths30:22 Hot Baths and Steam Showers35:37 Active Recovery and Recovery Runs35:41 Active Recovery: Rethinking Recovery Methods38:10 The Overrated Nature of Active Recovery39:29 The Role of Movement in Recovery40:48 Yoga: A Mixed Bag for Recovery44:50 Compression Therapy: Benefits and Limitations47:32 The Efficacy of Manual Therapy and Massage53:18 Sleep Monitoring Devices: Are They Worth It?01:00:19 Rest and Sedentarism: Finding Balance01:03:03 Supplements: Overrated or Essential? Work 1:1 with Aaron ⬇️https://strakernutritionco.com/nutrition-coaching-apply-now/Done For You Client Check-In System for Coaches ⬇️https://strakernutritionco.com/macronutrient-reporting-check-in-template/Paragon Training Methods Programming ⬇️https://paragontrainingmethods.comFollow Bryan's Evolved Training Systems Programming ⬇️https://evolvedtrainingsystems.comFind Us on Social Media ⬇️IG | @Eat.Train.ProsperIG | @bryanboorsteinIG | @aaron_strakerYT | EAT TRAIN PROSPER PODCAST

Show SummaryOn today's episode, we're featuring a conversation with Navy Veteran David Boone, a retired Rear Admiral and President and CEO of the San Diego Military Advisory Council or SDMAC. SDMAC is a nonprofit that advocates on behalf of the service members, veterans, and their families in the greater San Diego region. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestSan Diego Military Advisory Council (SDMAC) President and CEO David Boone is the CEO of SDMAC (sdmac.org) which is a nonprofit that advocates, informs and connects the San Diego military with the community, industry and civic leaders. Previously, he provided consulting services for a wide portfolio of clients in the engineering and construction industry. He was the Executive Vice President and Chief Growth Officer for Michael Baker International responsible for both public and private sector development in the consultant and engineering industry from highway and bridges to water, construction services and planning. Prior to that, he was President of CB&I Federal Services and its successor organization, APTIM Government Services. He joined the CB&I team in December 2013 following a 30 year career in the Navy. He began in Strategic Development, and Business Development then promoted to Chief Operating Officer and then President in the Federal sector of Engineering and Construction, Environmental Services, Energy and Base Operating Services.Mr. Boone retired from the US Navy in 2013 as a Navy Civil Engineer Corps Rear Admiral. His last active duty assignment was the Director of Shore Readiness where he was responsible for overseeing facilities and energy funding and policy for 70 bases worldwide – a $9 billion annual budget. His tours as Commanding Officer included Underwater Construction TEAM ONE (Seabees), NAVFAC MARIANAS (Guam), and NAVFAC Mid-Atlantic.Raised in Yokohama, Japan, high school in Oregon, Mr. Boone first attended the University of Oregon and the Oregon Institute of Marine Biology. He then transferred and graduated from Cal Poly SLO in Civil Engineering with Masters degrees in Coastal Engineering and Construction Management from the University of California, Berkeley. He is a registered professional engineer (Virginia and Florida). He was a Navy contracting officer, a Navy Diver, and maintains a TOP SECRET security classification. He received numerous personal Navy awards, including the Nippon Zenkokai Award from the Office of the Prime Minister of Japan. He is currently a member of the Industry Leaders Council with ASCE Industry Leaders Council | ASCE.Links Mentioned During the EpisodeSan Diego Military Advisory CouncilSan Diego Emergency Action GroupPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Seeking Support. Transitioning from military service can evoke strong emotions. PsychArmor Institute's “Seeking Support” offers service members the tools and resources needed to seek support during and after military transition and into civilian life.   You can find a link to the resource our show notes https://learn.psycharmor.org/courses/Seeking-Support   You can find the resource here:  https://psycharmor.org/podcast/chris-jachemic Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

**In this episode, Dr. Lisa Faast sits down with Craig Presser and Ryan from Skinesa to explore how a dermatologist-developed probiotic is redefining skin health — and helping independent pharmacies grow revenue through innovative wellness solutions. In this conversation: -How Skinesa supports acne, eczema, and rosacea through the gut-skin connection -The science behind dermatology probiotics and what makes Skinesa unique -How pharmacies can easily integrate Skinesa into their supplement lineup -Education strategies to help patients understand gut and skin wellness** **Show Notes:** 1. **Intro** [0:00] 2. **Introduction to Skinesa and Its Unique Probiotic** [0:01] 3. **Clinical Breakdown and Research Background** [2:57] 4. **Challenges and Efficacy in the European Market** [4:45] 5. **Personal Experiences and Clinical Insights** [7:11] 6. **Business Opportunities for Independent Pharmacies** [11:04] 7.**Marketing and Distribution Strategies** [14:24] 8.**Patient Testimonials and Clinical Evidence** [15:21] 9.**Conclusion and Contact Information** [18:50] **Website mentioned in this episode:** Contact Skinesa https://www.skinesa.com/  ----- #### **Becoming a Badass Pharmacy Owner Podcast is a Proud to be Apart of the Pharmacy Podcast Network**

Commentary by Dr. Tong Liu.

The November 2025 Recall revisits four insightful episodes centered on muscle and neuromuscular diseases. Kicking off the episode is a two-part series on myositis, where Dr. Stacey Clardy speaks with Dr. Andrew Mammen. The episode continues with an interview featuring Dr. Eric Voorn, who discusses the effectiveness of combining personalized, home-based aerobic exercise with coaching to improve physical fitness in individuals with neuromuscular diseases. The episode wraps up with Dr. Elia Sechi discussing the critical role of interpreting lab test results, understanding assay performance, and recognizing the real-world impact of false positives in myasthenia gravis diagnostics.  Podcast links: Updates on All Things Myositis – Part 1  Updates on  All Things Myositis - Part 2 Efficacy of Aerobic Exercise and Coaching on Physical Fitness in Neuromuscular Disease  False Positivity of Acetylcholine Receptor Autoantibodies in Clinical Practice Article links: Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice Show citations:  Oorschot S, Brehm MA, van Groenestijn AC, et al. Efficacy of Combined Aerobic Exercise and Coaching on Physical Fitness in People With Neuromuscular Diseases: A Randomized Clinical Trial. Neurology. 2025;105(1):e213781. doi:10.1212/WNL.0000000000213781 Zara P, Chessa P, Deiana GA, et al. Risk of False Acetylcholine Receptor Autoantibody Positivity by Radioimmunoprecipitation Assay in Clinical Practice. Neurology. 2025;104(9):e213498. doi:10.1212/WNL.0000000000213498 Disclosures can be found at Neurology.org.   

Episode Notes:Dr Ho describes an empirical research agenda focused on how security actually operates in organisations. He explains his experience with getting this research off the ground to allow them to perform the research in this setting.Study setting and scope: eight-month randomised controlled trial at UC San Diego Health involving ~19,500 employees and ten distinct phishing campaign lures.Annual awareness training: the study found no significant relationship between how recently staff completed the mandated course and their likelihood of failing a simulated phishing campaign.Embedded training (when someone clicks a phishing simulation and is immediately redirected to training): the measurable improvement was very small (≈2% reduction in failure rate) and varied significantly by lure and engagement.Engagement challenge: The vast majority of embedded-training sessions were extremely short or incomplete, a key factor in explaining limited effect size.Variability of lure difficulty: Some phishing lures elicited very low click-rates (~1.8%) while others up to ~30.8%, indicating that the phishing stimulus matters as much as, or more than, the training intervention.Practical takeaway: Organizations should treat training (especially annually mandated modules) as only one part of a broader defence strategy, and design empirical measurement systems (including controls, realistic lures, and sustained engagement) before assuming large effect sizes.About our Guest:Dr Grant Ho Profile: https://cs.uchicago.edu/people/grant-ho/Papers or resources mentioned in this episode:Ho, G.; Mirian, A.; Luo, E.; Tong, K.; Lee, E.; Liu, L.; Longhurst, C.A.; Dameff, C.; Voelker, G.M. (2025). Understanding the Efficacy of Phishing Training in Practice: A Randomized Controlled Trial at a Large Health Organisation. Presented at the IEEE Symposium on Security & Privacy (May 2025). Full PDF: https://people.cs.uchicago.edu/~grantho/papers/oakland2025_phishing-training.pdfOther: I mentioned some figures about the spending on cybercsecurity education and training, You can find those here.  Canadian Survey of Cyber Security and Cybercrime (CSCSC)https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=5244Get convenient Excel Tables of the Statistics from 2017 and 2019. https://www.serene-risc.ca/en/statistics-canadaOther Other:Dr Ho was great to chat with and has a long history of researching phishing, Some of his older work that is more technical in nature, as so we didn't talk about in the episode, but in the case that it  might be interesting to you, here are some links: Ho, G., Sharma, A., Javed, M., Paxson, V., & Wagner, D. (2017). Detecting Credential Spearphishing Attacks in Enterprise Settings. In Proceedings of the 26th USENIX Security Symposium (USENIX Security '17), Vancouver, BC, Canada, August 16-18, 2017. USENIX Association. ISBN 978-1-931971-40-9.PDF: https://www.usenix.org/system/files/conference/usenixsecurity17/sec17-ho.pdf USENIX+2USENIX+2Presentation page: https://www.usenix.org/conference/usenixsecurity17/technical-sessions/presentation/hoUSENIX+1Ho, G., Cidon, A., Gavish, L., Schweighauser, M., Paxson, V., Savage, S., Voelker, G. M., & Wagner, D. (2019). Detecting and Characterizing Lateral Phishing at Scale. In Proceedings of the 28th USENIX Security Symposium (USENIX Security '19), Santa Clara, CA, USA, August 14-16, 2019. USENIX Association. ISBN 978-1-939133-06-9.PDF: https://www.usenix.org/system/files/sec19-ho.pdf USENIX+1Presentation page: https://www.usenix.org/conference/usenixsecurity19/presentation/ho USENIX

This is the final installment of our 4-part series, "Trading Traditional Topicals for Targeted Therapies: Improving Disease Management for AD." In this episode, "Moving into the Non-Steroidal Topical Therapy Age," we dive into the current and emerging landscape of targeted topical therapies for AD patients. Our experts review the latest clinical data, discuss how they are practically integrating these agents into their practice, and analyze the resulting impact on patient outcomes and their overall approach to AD management. Listen in as board-certified dermatologists, Mona Shahriari, MD and G. Michael Lewitt, MD discuss: Overview of targeted topical therapies, including next generation topicals Efficacy of targeted topicals compared to topical steroids Safety, limitations, and compatibility with other therapies How to integrate targeted topicals into clinical practice Pearls for treating pediatric and adult patients across the indicated age range This podcast is supported by an educational grant from Arcutis Biotherapeutics, Inc.

Send us a textWelcome back Rounds Table Listeners! In this throwback episode (initial release 14 Mar 2024), Dr. Mike Fralick and special guest, Dr. Laiya Carayannopoulos from the Intern at Work Podcast, discuss two papers: one exploring the role of non-invasive ventilation in comatose patients after acute poisoning, and and one on the use of the PEN-FAST Score in the point-of-care risk assessment of penicillin allergy. Two papers, here we go!Effect of Noninvasive Airway Management of Comatose Patients With Acute Poisoning (0:00 – 16:25).Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy (16:26 – 24:17).And for the Good Stuff:Celebrating Research Success! (24:18 – 25:14).Non-inferiority results: everything you need know in 5 minutes! and Is Noninferior Not Inferior? (25:15 – 26:48).Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Topics covered:  Are oral GLP-1s as effective as injectables? What's the deal with the new report on protein powders containing lead? Should I worry about not having carbs with my protein after a workout? Are energy drinks really killing my gains in the gym and workouts? Consumer Report on protein powders Podcast with Dyllon Sanford on GLP-1-Part 1.  European Food Safety Authority

Show SummaryOn today's episode, we're featuring a conversation with Army Combat Veteran Jaymes Poling and Modern Warrior LIVE — a powerful blend of personal storytelling and music that explores the emotional weight of war and the journey toward healing.Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestJaymes Poling is a former infantry leader in the 82nd Airborne Division who served three years in Afghanistan. After coming home, he turned to writing to make sense of his experience, which led to the creation of Modern Warrior LIVE — a powerful blend of personal storytelling and music that explores the emotional weight of war and the journey toward healing.He's since become a speaker and mental health advocate, working with veterans, first responders, and trauma survivors across the country. Through hundreds of engagements nationwide, Jaymes brings a raw, honest voice to conversations about leadership, community, and post-traumatic growth. Links Mentioned During the EpisodeModern Warrior Live Web SitePsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Supporting Someone with Invisible Wounds. Not all wounds can be seen, and invisible wounds are just as serious as visible ones. This course introduces the four main types of invisible wounds - Posttraumatic Stress Disorder, Traumatic Brain Injury, Substance Use Disorder, and Depression.   You can find the resource here:  https://learn.psycharmor.org/courses/supporting-someone-with-invisible-wounds    Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In episode 65 we discuss varenicline and bupropion for alcohol use disorder.  Söderpalm B, Lidö H, Franck J, Håkansson A, Lindqvist D, Heilig M, Guterstam J, Samuelson M, Askerup B, Wallmark-Nilsson C, de Bejczy A. Efficacy and safety of varenicline and bupropion, in combination and alone, for alcohol use disorder: a randomized, double-blind, placebo-controlled multicentre trial. Lancet Reg Health Eur. 2025 May 13;54:101310.     We also discuss medical marijuana for anxiety in Pennsylvania, and RFK's embrace of psychedelic therapy.  Annals of Internal Medicine: Medical Cannabis Certifications After Pennsylvania Added Anxiety Disorders as a Qualifying Condition  Annals of Internal Medicine: High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes: A Systematic Review  MedPageToday: Will RFK Jr.'s Push for Psychedelic Therapy Help or Hamper the Emerging Field?  ---  This podcast offers category 1 and MATE-ACT CME credits through MI CARES and Michigan State University. To get credit for this episode and others, go to this link to make your account, take a brief quiz, and claim your credit. To learn more about opportunities in addiction medicine, visit MI CARES.  CME: https://micaresed.org/courses/podcast-addiction-medicine-journal-club/   ---  Original theme music: composed and performed by Benjamin Kennedy  Audio editing: Michael Bonanno  Executive producer: Dr. Patrick Beeman  A podcast from Ars Longa Media  ---  This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice.   ---  The best part of any journal club is the conversation. Send us your comments on social media or join our Facebook group.  Email: addictionmedicinejournalclub@gmail.com   Facebook: @AddictionMedJC  Facebook Group: Addiction Medicine Journal Club  Instagram: @AddictionMedJC   Threads: @AddictionMedJC  YouTube: addictionmedicinejournalclub   Twitter/X: @AddictionMedJC    ---  Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Here is a real-world clinical case with a tricky differential: Our team recently readmitted a patient 6 days postpartum/post C-section (which was done for ICP and fetal macrosomia at close to 4500 grams, with A2GDM). She had elevated blood pressures, a frontal headache, some midepigastric pain/RUQ discomfort. Pretty clear picture right: sounds like preeclampsia (PreE) with severe features based on BP elevation and symptoms. So, we started her on mag-sulfate per protocol. Well, her transaminases were in the 400-600s, which was significantly higher than they were at delivery. They then peaked the next day at 900! OK, it still meets criteria for PreE with severe features. But could this also be postpartum Acute fatty Liver of Pregnancy (AFLP)? The clinical picture of these 2 conditions may overlap but there are distinct differences here. AFLP is potentially fatal, so we have to get that diagnosis correct. How can we distinguish AFLP from PreE with severe features or HELLP? Listen in for details.1. https://www.preeclampsia.org/the-news/health-information/acute-fatty-liver-of-pregnancy-can-be-confused-with-preeclampsia-and-hellp-syndrome2. Yemde A Jr, Kawathalkar A, Bhalerao A. Acute Fatty Liver of Pregnancy: A Diagnostic Challenge. Cureus. 2023 Mar 26;15(3):e36708. doi: 10.7759/cureus.36708. PMID: 37113350; PMCID: PMC10129069.3. Maalbi O, Elachhab N, Elkabbaj A, Arfaoui M, Hindi S, Lahbabi S, Oudghiri N, Tachinante R. Management of Acute Fatty Liver of Pregnancy: A Retrospective Study of 12 Cases Compared With Data in the Literature. Cureus. 2025 Jun 11;17(6):e85753. doi: 10.7759/cureus.85753. PMID: 40656400; PMCID: PMC12247011.4. Siwatch S, De A, Kaur B, et al. Safety and Efficacy of Plasmapheresis in Treatment of Acute Fatty Liver of Pregnancy-a Systematic Review and Meta-Analysis.Frontiers in Medicine. 2024;11:1433324. doi:10.3389/fmed.2024.1433324.5. Sarkar M, Brady CW, Fleckenstein J, et al.6. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases.Hepatology (Baltimore, Md.). 2021;73(1):318-365. doi:10.1002/hep.31559.STRONG COFFEE PROMO: 20% Off Strong Coffee Company https://strongcoffeecompany.com/discount/CHAPANOSPINOBG

AI in behavioral health demands a balanced strategy that protects consumers, enables innovation, and expands access at scale.  In this episode, Dr. Zach Boyd, Director of Utah's Office of Artificial Intelligence Policy, shares how his team is creating practical guardrails for responsible AI in healthcare. He traces his path from theoretical math to social science, noting that behavioral health is the front line for AI's impact. Early milestones include broad stakeholder surveys, privacy and advertising protections, detailed guidance for professionals, and a safe harbor to reduce regulatory uncertainty. Dr. Boyd highlights opportunities in clinical automation and consumer tools, while warning about risks like deepfakes and urging leaders to balance safety, efficacy, and access. Tune in and learn how thoughtful policy can accelerate safer, more equitable behavioral health innovation! Resources: Connect with and follow Dr. Zach Boyd on LinkedIn. Learn more about Utah's Office of Artificial Intelligence Policy here. Email Utah's Office of Artificial Intelligence Policy directly here.

Featuring an interview with Dr Eunice S Wang, including the following topics: Hypomethylating agent/venetoclax combinations for the treatment of acute myeloid leukemia (AML); integration in community practice (0:00) All-oral regimen of decitabine/cedazuridine with venetoclax for patients with newly diagnosed AML not eligible for intensive induction chemotherapy (9:39) Efficacy of targeted therapy options for AML; potential role of MRD (minimal residual disease) assays in monitoring treatment response (13:07) Treatment approach for patients with FLT3-mutant AML; mutation profiles and predicting response to quizartinib (20:14) Targeting the differentiation of AML tumor cells with IDH and menin inhibitors; associated differentiation syndrome (29:24) Efficacy and tolerability of the IDH inhibitors ivosidenib and olutasidenib (36:54) Key clinical data with approved and investigational menin inhibitors for AML; current and potential integration of menin inhibitors in the AML treatment algorithm (42:30) CME information and select publications

Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent studies and shared decision-making. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002716. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ From Criteria to Clinic: How Updated Slim CRAB Criteria Influence Multiple Myeloma Diagnostic Activity https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.7556 International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM) https://pubmed.ncbi.nlm.nih.gov/33067414/ Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/39652675/ Lenalidomide-Dexamethasone Versus Observation in High-Risk Smoldering Myeloma After 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study https://pubmed.ncbi.nlm.nih.gov/36067617/ Long-Term Outcome With Lenalidomide and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/23648667/ CD38-Directed Therapies for Management of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/34235096/ Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma – Results of the Ascent Trial https://ashpublications.org/blood/article/140/Supplement%201/1830/492739/Fixed-Duration-Therapy-with-Daratumumab Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (Krd) Followed by Transplant, Krd Consolidation, and Rd Maintenance https://pubmed.ncbi.nlm.nih.gov/39038268/ Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma https://ashpublications.org/blood/article/144/Supplement%201/1027/531466/Early-Safety-and-Efficacy-of-CAR-T-Cell-Therapy-in

Send us a textIn this episode of PT Snacks podcast, we continue our discussion on the sacroiliac (SI) joint, discussing optimal manual techniques and exercises to help patients experiencing SI joint pain. We'll break down the function of the SI joint, explore the latest research on manual therapy, and explain why a combination of manual therapy and exercise is most effective. Join us as we cover high-level reviews and specific techniques to help your patients move better and feel better. Don't forget to hit the subscribe button, leave a review, and check out the special MedBridge discount in the show notes!00:00 Introduction and Podcast Overview00:26 Listener Feedback and Today's Topic Introduction01:29 Understanding the Sacroiliac (SI) Joint02:03 Manual Therapy Techniques for SI Joint05:52 Mechanisms and Theories Behind Manual Therapy13:46 Exercises for SI Joint Stabilization15:44 Combining Manual Therapy and Exercise16:57 Conclusion and Additional ResourcesTrager RJ, Baumann A, Rogers H, et al. Efficacy of manual therapy for sacroiliac joint pain syndrome: a systematic review and meta-analysis of randomized controlled trials. J Man Manip Ther. 2024;32(2):71-85.Nejati P, Safarcherati A, Karimi F. Effectiveness of exercise therapy and manipulation on sacroiliac joint dysfunction: a randomized controlled trial. Pain Physician. 2019;22(1):53-61.Kamali F, Zamanlou M, Ghanbari A, Alipour A, Bervis S. Comparison of manipulation and stabilization exercises in patients with sacroiliac joint dysfunction: a randomized clinical trial. J Bodyw Mov Ther. 2019;23(1):177-182.Bialosky JE, Bishop MD, Price DD, Robinson ME, George SZ. The mechanisms of manual therapy in the treatment of musculoskeletal pain: a comprehensive model. J Orthop Sports Phys Ther. 2009;39(3):123-130.Testa M, Rossettini G. Enhance placebo, avoid nocebo: how contextual factors affect physiotherapy outcomes. Phys Ther. 2016;96(11):1541-1549.Shahali S, Ebrahimian MR, Hosseinifar M, et al. Effects of motor control exercise on pain and disability in patients with sacroiliac joint pain: a systematic review and meta-analysis. Musculoskelet Sci Pract. 2021;56:102419.Visser LH, Woudenberg NP, de Bont J, et al. Treatment of the sacroiliac joint in patients with leg pain: a randomized controlled trial. Eur Spine J. 2Go to PT Final Exam using this link to access great studying options to conquer the NPTE!Support the showStay Connected! Follow so you never miss an episode. Send your questions via email to ptsnackspodcast@gmail.com Join the email list HERE Need CEUs or NPTE Prep? Save over $100 on unlimited CEUs with MedBridge using code PTSNACKSPODCAST at checkout. Students: Get a full year of access for less with code PTSNACKSPODCASTSTUDENT. Prepping for the NPTE? PT Final Exam offers all the tools you need. Use code PTSnacks at checkout to get a discount! Support the ShowShare the episode with someone who'd benefit. Contributing directly to the "support" link. Thanks for tuning in—your support makes this all possible!

Show SummaryOn today's episode, we're featuring a conversation with Dr Ed Tick, internationally recognized educator, author and expert on the military, veterans, PTSD, Viet Nam, and the psychology, spirituality and history of global trauma, warrior traditions, and military-related issues. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestEdward Tick, PhD is a nonfiction writer and poet. He is a transformational healer, holistic psychotherapist, educator, consultant and international journey guide. Dr. Tick has been working to heal the invisible wounds of war and violent trauma for over forty years. He is honored for his groundbreaking work in the spiritual, holistic, and community-based healing of veterans and other survivors of severe violence who suffer Post-Traumatic Stress Disorder (PTSD) and moral injury. He has published breakthrough books in this field, including the award-winning War and the Soul. His work introduced the ancient concept of soul wounding and how to heal it to our modern military, veteran and trauma studies worlds. Dr. Tick is an internationally recognized educator, author and expert on the military, veterans, PTSD, Viet Nam, and the psychology, spirituality and history of global trauma, warrior traditions, and military-related issues. For four decades he has conducted trainings, retreats and workshops across the country and overseas. He has trained staff, taught and worked with wounded warriors at major Department of Defense and Veteran Administration facilities and at colleges, universities, hospitals, health care and community centers across the country and overseas. Defense Dept. and VA facilities use his pioneering work and he has served as the US military's subject matter expert trainer on PTSD and Moral Injury for the past decade. Ed cofounded the nonprofit Soldier's Heart, Inc. with his partner Kate Dahlstedt and for 13 years served as its director from their national offices in Troy, New York. He now consults internationally on these issues. Links Mentioned During the EpisodeDr. Tick's Web SiteBooks by Dr. Tick Close Encounters in War Journal  Healing a Soldier's Heart on PBSPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is a previous podcast episode on the topic of Moral Injury, episode 188 with Dr. Shira Maguen. In this episode, we discuss the diagnosis and treatment of Moral Injury as well as how the clinical community have come to understand the concept.    You can find the resource here:  https://psycharmor.org/podcast/dr-shira-maguen Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

Featuring an interview with Dr Aaron Lisberg, including the following topics: Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) for Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of the TROPION-Lung01 and TROPION-Lung05 Trials (0:00) Ahn M-J et al. Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05. ESMO Asia 2024;Abstract LBA7 Ahn M-J et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol 2025;[Online ahead of print]. Abstract Sacituzumab Tirumotecan for Previously Treated Advanced EGFR-Mutated NSCLC: Results from the Randomized OptiTROP-Lung03 Study (7:08) Fang W et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: Multicentre, open label, randomised controlled trial. BMJ 2025;389:e085680. Abstract Zhang L et al. Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study. ASCO 2025;Abstract 8507. Combination of Dato-DXd and Immunotherapy as First-Line Therapy for Patients with Advanced NSCLC (13:12) Cuppens K et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + durvalumab ± carboplatin in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohorts 2 and 4). ESMO Targeted Anticancer Therapies Congress 2025;Abstract 8O. Okamoto I et al. TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol 2024;20(37):2927-36. Abstract Levy BP et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol 2023;19(21):1461-72. Abstract Aggarwal C et al. AVANZAR: Phase III study of datopotamab deruxtecan (Dato-DXd) + durvalumab + carboplatin as 1L treatment of advanced/mNSCLC. World Conference on Lung Cancer (WCLC) 2023;Abstract P2.04-02. TROP2-Targeting Antibody-Drug Conjugates as Neoadjuvant and/or Adjuvant Therapy for Patients with Resectable NSCLC (19:08) A phase III, randomised, open-label, global study of adjuvant datopotamab deruxtecan (Dato-DXd) in combination with rilvegostomig or rilvegostomig monotherapy versus standard of care, following complete tumour resection, in participants with Stage I adenocarcinoma non-small cell lung cancer who are ctDNA-positive or have high-risk pathological features (TROPION-Lung12). NCT06564844 Cascone T et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: The platform phase 2 NeoCOAST-2 trial. Nat Med 2025;31(8):2788-96. Abstract CME information and select publications

Show SummaryThis episode features a conversation with Kathleen Ellertson, the Founder and President of the Veteran Art Institute. The Veteran Art Institute is a 501(c)3 Nonprofit dedicated to honoring and empowering active-duty military and veterans through the arts.Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestKristin Saboe, PhD, is an Industrial-Organizational Psychologist that uses science and research to drive large-scale impact at the intersection of strategy, policy, and research. She is the Head of Employee Voice at Google, a professor at Georgetown University, and a U.S. Army Reserve futures innovation officer. Dr. Saboe previously led Employee Listening, Research, and Strategy at The Boeing Company. In this role she authored and led Boeing's talent strategy for veterans and military connected employees. Prior to this, she served as an Army Research Psychologist establishing strategy and policy for performance optimization, analytics, and talent management. She holds a PhD in Industrial-Organizational Psychology, is a fellow of the American Psychological Association, Society for Industrial-Organizational Psychology, and the Society for Military Psychology. She received the early career award from both the Society for Military Psychology and the Society for Industrial-Organizational Psychology and was recognized for her leadership impact by the President George W Bush Institute in 2019. She is co-editor of the book Military Veterans Employment: A Guide for the Data-Driven Leader and provides pro bono support leading Government Relations and Advocacy for the Society for Industrial-Organizational Psychology, as founding board member of the Military Psychology Foundation, and for several nonprofits.Links Mentioned During the EpisodeMilitary Veteran Employment: A Guide for the Data-Driven LeaderPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the previous episode in this MCON series, episode 236 with Air Force Veteran Chris Jachimiec, a dedicated speaker and proponent for suicide prevention based on his own experience as a suicide loss survivor   You can find the resource here:  https://psycharmor.org/podcast/chris-jachemic Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In his weekly clinical update, Dr. Griffin with Vincent Racaniello chat about Jane Goodall's death and the Nobel prize in Physiology/Medicine for understanding immune system control before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, if 2 doses of the influenza vaccine are better for protection of first season children, if COVID-19 negatively impacts pregnancy and the unborn child, efficacy of long-acting monoclonal antibody against symptomatic COVID-19, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, long COVID in pediatrics, association of COVID-19 with new-onset vascular dementia and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Jane Goodall's legacy: three ways she changed science (Nature) They understood how the immune system is kept in check (The Nobel Prize) Daniel Griffin: The Nobel Prize for Understanding Autoimmune Disease (WNYC: New York Public Radio) Kennedy's Ties to Ally Leading Vaccine Lawsuits Raise Ethical Concerns (NY Times) Ebola outbreak in southern Congo shows signs of containment with no new cases, WHO reports (AP News) Ebola Disease (WHO: African Region) Premature baby dies from measles in Alberta as cases throughout province near 2,000(Global News) DOH Issues Advisory After Measles Detection in City of Oswego Wastewater (Finger lakes dailynew.com) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) Influenza-Associated Pediatric Deaths — United States, 2024–25 Influenza Season (CDC: MMWR) ACIP Recommendations Summary (CDC: Influenza) American Academy of Pediatrics Flu and Children (CDC: Influenza (flu)) Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza (JAMA: Open Network) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV vaccination in Adults aged 50-59 Years (CDC: ACIP) Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases) Efficacy and safety of respiratory syncytial virus vaccines(Cochrane Library) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Neonatal outcomes among pregnant women with COVID-19 (BMC Pregnancy and Childbirth) Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19 (CID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity (CID) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR) (LANCET: Infectious Diseases) Prevalence and duration of clinical symptoms of pediatric long COVID (Frontiers in Pediatrics) COVID-19 infection associated with increased risk of new-onset vascular dementia in adults ≥50 years(NPJ| dementia) Reaching out to US house representative Letters read on TWiV 1260 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Tom Lewis, DVM, DACVD is back on the podcast! Last year, Dr. Lewis joined the podcast last year to discuss the release of Zenrelia. One year later, he is back to discuss his experience with having this medication for a year and the relief it has provided for hundreds of his canine patients. Also, we discuss the recent change to the US boxed label warning which removed the vaccine induced disease portion of the label.Learn more on this week's episode of The Derm Vet podcast!Studies mentioned in podcast: Recent study regarding vaccine booster response in dogs receiving Zenrelia: Fent, G.M., Jacela, J., Plazola-Ortiz, R. et al. Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls. BMC Vet Res 21, 481 (2025). https://doi.org/10.1186/s12917-025-04929-zRecent study regarding safety of Zenrelia: S. Forster, C. M. Trout, S. Despa, A. Boegel, D. Berger, and S. King, “ Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial,” Veterinary Dermatology (2025): 1–13, https://doi.org/10.1111/vde.70009.Timestamps00:00 Intro02:46 Zenrelia box label warning change08:14 What does the box label warning change mean and why it's only in the US?12:10 Looking at every patient as an individual17:00 How comfortable do you feel using Zenrelia long-term?22:14 Outro

Dr. Jeffrey Gladden and Nodari Rizun explores into the fascinating world of Shilajit, a natural product with a rich history and numerous health benefits. They explore its origins, the science behind its effectiveness, and its role as a regenerative adaptogen. The conversation also touches on the historical significance of Shilajit in medicine, its unique properties, and modern research supporting its use. Listeners will learn about the practical applications of Shilajit, how to consume it, and its potential as a delivery system for other herbal extracts.   For Audience ·       • Use code 'Podcast10' to get 10% OFF on any of our supplements at https://gladdenlongevityshop.com/ !  ·      • https://app.impact.com/campaign-promo-signup/Purblack.brand   Takeaways ·       Shilajit is a natural product found in mountainous regions. ·       It is a combination of fulvic and humic acids. ·       Shilajit has been used for centuries in traditional medicine. ·       It acts as a regenerative adaptogen, helping the body adapt to stress. ·       Genuine Shilajit is always in resin form, not powder or tablets. ·       The quality of Shilajit can vary significantly between sources. ·       Shilajit can enhance the effectiveness of other herbal extracts. ·       It has potential benefits for mitochondrial function and energy production. ·       Shilajit may help regulate weight and reduce cravings for sugar. ·       Research on Shilajit is extensive, with studies in multiple languages.   Chapters 00:00 Introduction to Shilajit and Its Origins 05:11 Nodari's Journey from Law to Natural Health 08:01 Understanding Shilajit: Myths and Realities 10:55 The Science Behind Shilajit 13:42 The Unique Properties of Genuine Shilajit 16:08 Shilajit as a Biogenic Stimulant 18:58 Adaptogens and Their Role in Health 21:56 Research and Studies on Shilajit 25:54 The Role of Shilajit in Health 30:25 Understanding Mitochondrial Function and Energy Production 33:21 Pure Black: Quality and Efficacy of Shilajit 36:41 Consumption Methods and Innovations in Shilajit 40:24 Shilajit as a Delivery System and Amplifier 43:58 Research Insights on Shilajit and Health Benefits   To learn more about Nodari Rizun: Website: https://purblack.com/ Instagram: https://www.instagram.com/purblackofficial/ Got a question for Dr. Gladden? Submit it using the link below and it might be answered in our next Q&A episode! https://form.typeform.com/to/tIyzUai7? Reach out to us at:    Website: https://gladdenlongevity.com/     Facebook: https://www.facebook.com/Gladdenlongevity/    Instagram: https://www.instagram.com/gladdenlongevity/?hl=en     LinkedIn: https://www.linkedin.com/company/gladdenlongevity    YouTube: https://www.youtube.com/channel/UC5_q8nexY4K5ilgFnKm7naw    

A meta-analysis of low-carb diets for diabetes remission found little to no effect at 12 months, clinically important harms to quality of life, and the deal-killer––an increase in LDL cholesterol.

Is the "best" hospital just about technology and surgical success? Ben Harder, the journalist who oversees the methodology and data for the U.S. News Best Children's Hospitals Rankings (2025), joins Katie to break down what truly defines quality in pediatric care. Ben shares his deeply personal family story—a tragedy 50 years in the past that drives his commitment to making data-driven information accessible today. This episode is a crucial guide for parents, explaining the three core pillars of the rankings: structure/resources, processes of care, and patient outcomes. We dive into why essential human-focused services like Child Life Specialists, chaplains, and family advisory boards are included in the scorecard and how they influence the rankings. Ben illuminates the challenge faced by these vital "cost centers" in a revenue-driven healthcare system, and offers a powerful message: parents are the strongest possible advocates for their children, and they should use every resource available—including the U.S. News data—to make informed, collaborative choices for their child's care team. Guest Links U.S. News Best Children's Hospitals Rankings: All data is freely available for families to research hospitals by region and specialty. Website: US News Press Release Episode Highlights & Key Takeaways The Personal Motivation: Ben shares the heartbreaking story of his cousin, whose permanent brain injury after a heart surgery complication 50 years ago lacked the complete care team needed to ensure a good outcome—a void the U.S. News data is designed to fill today. The Three Pillars of Ranking: US News analyzes over 1,000 data points grouped into: 1) Resources/Structure (nurses, expertise, technology, child life services), 2) Processes of Care (following best practices, infection control), and 3) Outcomes (survival, length of stay, quality of life). The Honor Roll: The 2025 Honor Roll features the top 10 hospitals recognized for high performance across multiple specialties, including: Boston Children's Hospital, The Children's Hospital of Philadelphia (CHOP), Cincinnati Children's, Texas Children's Hospital, and others. A Piece of the Puzzle: The rankings are one resource to use alongside insurance coverage, geographic location, and most importantly, consulting your child's doctors and trusting your parental intuition. The Value of Human Support: Services like Child Life Specialists, support groups, and family advisory boards are included in the structural data points, serving as a motivator for hospitals to invest in comprehensive, family-centered care. Advocacy is Essential: Ben gives parents permission to advocate relentlessly, reminding them they know their child best. Collaborating with—not simply questioning—the care team can be life-saving. Chapters: Timestamp Topic 0:00 Ben Harder's Personal Connection to Hospital Rankings 1:03 The Official Launch of the U.S. News Best Children's Hospitals 2025 3:20 US News Honor Roll: The Top 10 Children's Hospitals 4:26 FREE COURSE Ad: Shots, Blood Draws & Comfort Positioning 5:35 Meet Ben Harder: Journalist, Father, and Best Hospitals Lead 7:59 The 3 Pillars of US News Ranking Methodology (1000+ Data Points) 11:37 The Role of Expert Work Groups in Defining Data 13:58 The Future of Family Expertise in Shaping Rankings 16:59 How Families Should Use the U.S. News Rankings 21:09 Why Child Life Services and Support Resources Matter in Rankings 25:12 Why Support Services are Overlooked: Revenue vs. Cost Centers 27:54 Ben Harder's Personal Story: The Tragic Need for Comprehensive Care 31:00 The Efficacy and Impact of Child Life Specialists 34:36 What Families Should Expect and Ask For: Advocacy Permission 38:23 Where to Find the U.S. News Best Children's Hospitals Rankings 38:58 Disclaimer   Resources for You 1. Unlock Two FREE Courses (Value $250+) We want to equip you to better support your child during medical experiences! Get our popular courses "How to Prepare, Support, and Respond to Your Child During Shots, Blood Draws, and Vaccines" AND "How to Use Comfort Positioning in Pediatrics" completely free. How to Get It: Leave a written review for the Child Life On Call podcast on Apple Podcasts or Spotify. Take a quick screenshot of your submitted review. Email the screenshot to: podcast@childlifeoncall.com 2. Connect with Child Life On Call Website: ChildLifeOnCall.com Instagram: @ChildLifeOnCall Disclaimer: The content of this podcast is for informational purposes only. The host and guests are not licensed therapists or medical doctors. Always consult with your child's qualified medical professional for advice specific to your family's situation.  

Send us a textUnderstanding the Sacroiliac Joint: Causes, Diagnosis, and TreatmentIn this episode of PTs Snacks podcast, we cover the often misunderstood sacroiliac (SI) joint, explaining its anatomy and function. Listeners will learn about the causes of SI joint pain and the risk factors associated with it. We also discuss methods for diagnosing SI joint pain and effective treatments.00:00 Introduction to PTs Snacks Podcast00:58 Overview of the Sacroiliac (SI) Joint01:28 Anatomy and Function of the SI Joint02:59 Causes and Risk Factors of SI Joint Pain04:13 Symptoms and Differential Diagnosis06:48 Provocative Tests for SI Joint Pain09:31 Imaging and Injections for Diagnosis10:43 Treatment Options for SI Joint Pain11:32 Conclusion and Additional ResourcesResources:Nejati P, et al. Effectiveness of exercise therapy and manipulation on sacroiliac joint dysfunction: a randomized controlled trial. Pain Physician. 2019;22(1):53-61.Trager R, et al. Efficacy of manual therapy for sacroiliac joint pain syndrome: a systematic review and meta-analysis of randomized controlled trials. Musculoskelet Sci Pract. 2024;67:102815.Doğan N, et al. Effects of mobilization treatment on sacroiliac joint dysfunction syndrome. Pain Res Manag. 2021;2021:6613629.Javadov A, et al. The efficiency of manual therapy and sacroiliac and lumbar exercises in patients with sacroiliac joint dysfunction syndrome. Turk J Phys Med Rehabil. 2021;67(2):129-36.Cerasoli T, et al. Injective therapies for managing sacroiliac joint pain in spondyloarthropathy: a systematic review and meta-analysis. 2025.Gartenberg A, et al. Sacroiliac joint dysfunction: pathophysiology, diagnosis, and treatment. Curr Rev Musculoskelet Med. 2021;14(6):414-21.Liu Y, et al. Comparative efficacy of clinical interventions for sacroiliac joint pain: systematic review and network meta-analysis with preliminary design of treatment algorithm. Pain Physician. 2023;26(2):123-34.Polly D, et al. Two-year outcomes from a randomized controlled trial of minimallGo to PT Final Exam using this link to access great studying options to conquer the NPTE!Support the showStay Connected! Make sure to hit follow now so you don't miss an episode! Got questions? Email me at ptsnackspodcast@gmail.com or leave feedback HERE. You can also join the email list HERE Need CEUs Fast?Time and resources short? Medbridge has you covered: Get over $100 off a subscription with code PTSNACKSPODCAST: Medbridge Students: Save $75 off a student subscription with code PTSNACKSPODCASTSTUDENT—a full year of unlimited access for less! Prepping for the NPTE? Get all the study tools you need to master it at PT Final Exam. Use code PTSnacks at checkout to get a discount! Want to Support the Show?Help me keep creating free content by: Sharing the podcast with someone who'd benefit. Contributing directly via the link...

Show SummaryThis episode features a conversation with Kathleen Ellertson, the Founder and President of the Veteran Art Institute. The Veteran Art Institute is a 501(c)3 Nonprofit dedicated to honoring and empowering active-duty military and veterans through the arts.Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestKathleen Ellertson is the dedicated Founder and President of the Veteran Art Institute (VAI). Inspired by her father, an Army Air Forces Veteran and WWII Bronze Star Medal recipient, Kathleen has channeled her lifelong passion for the arts into a mission to honor veterans through creative expression. With a BFA in Art History and years of experience curating veteran art exhibits, including a notable year-long exhibit at the Pentagon, Kathleen has established VAI as a platform for veterans to showcase their work both online and in local galleries. Since its inception in 2019, VAI has not only hosted numerous art exhibitions but has also cultivated a nurturing community where veteran artists can share their stories and find solace. Kathleen's unwavering dedication to giving back to the veteran community continues to drive her work, making a meaningful impact through art and advocacy.Links Mentioned During the EpisodeVeteran Art Institute Web Site PsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course Telling Your Story. Your experience in the United States military is one only you can tell and it's up to you how much you choose to share with others. In this course, four Veterans share their personal stories and offer insight.   You can find the resource here:  https://learn.psycharmor.org/courses/va-s-a-v-e Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In today's episode, we're joined by Jianne Jamil, founder of DIOME, a premium supplement brand developing science-backed formulas to support the demands of modern life. Inspired by her mother's decades-long struggle with prescription sleep medication, she set out to create effective, natural alternatives without the negative side effects. Before founding DIOME, Jianne built her career in the luxury beauty industry across New York, Paris, and London with La Mer, Tom Ford and Bobbi Brown. DIOME launched with Rested, an award-winning doctor-formulated, sleep supplement developed with her expert scientific team, including naturopath Emilie Delanoue and medical doctor Dr. Jencikova.DIOME launched with Rested, a doctor-formulated, sleep-optimising supplement developed with her expert scientific team, including Emilie Delanoue and Dr. Jencikova.Stay tuned to hear Jianne's insights on where to start with your NPD, building a science-led wellness brand, and how to market those premium products.Jianne's advice: Product launch advice: Efficacy is everything; your product must truly deliver resultsHealth industry tip: Do thorough research before entering this highly regulated spaceRegulatory compliance advice: Check laws in every country where you plan to sellSupply chain tip: Confirm ingredient availability before committing to productionQuality control advice: Test, test, and test again to build customer trustEntrepreneurship lesson: Use both data and intuition when deciding launch timingStartup growth tip: One hero product can be enough to build a thriving businessCustomer loyalty advice: Focus on longevity and building a faithful customer baseBranding and marketing tip: Position your product carefully, especially for a premium science-based brandBusiness integrity lesson: Cut no corners — reputation is everythingAgency collaboration tip: Brief your creative team thoroughly so they reflect your visionFF&M enables you to own your own PR & produces podcasts.Recorded, edited & published by Juliet Fallowfield, 2024 MD & Founder of PR & Communications consultancy for startups Fallow, Field & Mason.  Email us at hello@fallowfieldmason.com or DM us on instagram @fallowfieldmason. FF&M recommends: LastPass the password-keeping site that syncs between devices.Google Workspace is brilliant for small businessesBuzzsprout podcast 'how to' & hosting directoryCanva has proved invaluable for creating all the social media assets and audio bites.MUSIC CREDIT Funk Game Loop by Kevin MacLeod.  Link &  LicenceText us your questions for future founders. Plus we'd love to get your feedback, text in via Fan MailSupport the show

In today's episode, we had the pleasure of speaking with Kanwal P. S. Raghav, MBBS, MD, about the role of fruquintinib (Fruzaqla) in the treatment of adult patients with pretreated, metastatic colorectal cancer (CRC). Dr Raghav is a professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine, associate vice president of the Department of Ambulatory Medical Operations, and executive medical director of the Department of Ambulatory Treatment Centers at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Raghav discussed the mechanism of action of fruquintinib, key efficacy data from the phase 3 FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials, the treatment settings where this agent is most frequently administered, and adverse effects to be aware of. He also noted how the role of fruquintinib in earlier lines of therapy has yet to be defined due to a lack of optimal predictive biomarkers. Dr Raghav concluded by emphasizing the importance of clinical trials for improving outcomes for patient with CRC.

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Efficacy vs. Potency⁠⁠ ⁠ from the Pharmacology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

In this episode, we are joined by Clark Neily, Senior Vice President for Legal Studies at the Cato Institute, to discuss the weaponization of the Department of Justice and the broader implications of plea bargaining and charge stacking in the U.S. legal system. We dive into the erosion of jury trials, the impact of coercive plea deals, and the challenges of maintaining justice and human dignity in a system increasingly reliant on non-public procedures. We also touch on the historical context of these issues and the potential for reform. 00:00 Introduction 00:31 The Efficacy of Acupuncture for Chronic Back Pain 04:54 Charlie Kirk Memorial Service 07:59 Foolishness of the Week 10:47 Clark Neily Introduction 12:38 Trump Truth Social Post 17:23 Plea Bargaining and Charge Stacking 22:44 Weaponization of the DOJ 26:00 Public Trust in DOJ Waning 28:41 The Constitution Right to a Jury Trial 30:45 The Role of the Supreme Court 36:39 Grand Jury Indictments 41:11 What's Next for the DOJ 45:59 Historical Context and Legal Reform 49:10 The Importance of Jury Duty Learn more about your ad choices. Visit podcastchoices.com/adchoices

Follow me on Twitter/X (@chinaadventures) where I post (among other things) daily reminders to pray for China.You can also email me @ bfwesten at gmail dot com. Last but not least, to learn more about our ministry endeavors or get one of my missionary biographies, visit PrayGiveGo.us! Why did I begin the Prison Pulpit series? The goal is to remind everyone to pray for persecuted believers as Hebrews 13:3 teaches us to do (“Remember those in prison, as bound with them, and those who are mistreated, since you also are in the body.”). I’ve done this by sharing imprisoned Pastor Wang Yi’s writings in China, as well as anecdotes from other persecuted ministers who have gone before, such as Richard Wurmbrand. Charlie Kirk on the Efficacy of Prayer In late August, just two weeks before his death, Charlie talked about prayer on his podcast in the aftermath of the Minneapolis church/school shooting in a conversation with Michael Knowles… https://thecharliekirkshow.com/podcasts/the-charlie-kirk-show/where-is-god-when-evil-happens-reacting-to-the-minneapolis-tragedy (9:53-10:51) Now I want to return to one of Richard Wurmbrand’s Sermons in Solitary Confinement… Talk With My Son Mihai (Dying Father Admonishes Son) From Wurmbrand’s book, Sermons in Solitary Confinement… https://richardwurmbrandfoundation.com/pdfs/ssc-english.pdf In God's Underground: Christ in the Communist Prisons https://richardwurmbrandfoundation.com/pdfs/IGU-english.pdf Follow China Compass Subscribe to China Compass on whichever platform you use, including Apple Podcasts! You can also contact me anytime on X: @chinaadventures or via email (bfwesten at gmail dot com). Hebrews 13:3!

In Session 311, I sit down with Christina Nylander and Leah Hussain from Apollo Behavior to talk about culturally sensitive approaches to Autism intervention. We dive into three case studies that show how flexible, individualized care can make a huge difference in building the rapport that's so important in our clinical work. Along the way, we share strategies for gaining parent buy-in, supporting bilingual language development, and using AAC devices to help children communicate more effectively with their families. Here's what we cover: The parent training shift when cultural sensitivity and rapport-building are prioritized. Christina and Leah's bilingual language development success stories, including Spanish- and Russian-speaking families. The role of AAC devices in improving communication, and one of these case studies progressed to no longer needing this technology. My random thoughts on video documentation and other creative methods to communicate client progress to stakeholders. Throughout the discussion, we reflect on the importance of balancing clinical recommendations with cultural and educational values. It's not just about treatment plans—it's about building trust, respecting families' perspectives, and helping kids thrive in ways that feel authentic to them. Sidenote: If you want to learn about what it's like to work at Apollo, or check out their open positions, click here. Key Takeaways Cultural sensitivity builds stronger collaboration with families. Bilingual and AAC strategies can unlock communication progress. Showing progress through videos and creative methods strengthens parent engagement. Individualized parent training, including in multiple languages, increases accessibility. If you're a BCBA, ABA therapist, or behavioral health professional, I think you'll find this conversation full of practical ideas for making your work more effective—and more meaningful. Bilingual & Dual‑Language Interventions Neely et al. (2020) – Impact of language on behavior treatment outcomes. Banerjee et al. (2021) – Extending Functional Communication Training to Multiple Language Contexts in Bilingual Learners with Challenging Behavior. Cengher (2024). On Bilingualism: Why and How to Teach Two Languages to Children with Autism Spectrum Disorder. Cultural Responsiveness, Humility & Systemic Equity in ABA Deochand, Neil & Costello, Mack S. (2022). Building a Social Justice Framework for Cultural and Linguistic Diversity in  ABA. Jimenez-Gomez, Corina & Beaulieu, L. (2022). Cultural responsiveness in applied behavior analysis: Research and practice. ABA Effectiveness & Need for Cultural Inclusion Yu, Qian; Li, Enyao; Li, Liguo; Liang, Weiyi (2020). Efficacy of Interventions Based on Applied Behavior Analysis for Autism Spectrum Disorder: A Meta‑Analysis. Spreckley, Michele & Boyd, Roslyn (2009). Efficacy of Applied Behavioural Intervention in Preschool Children with Autism for Improving Cognitive, Language, and Adaptive Behavior: A Systematic Review and Meta-Analysis. Bonus resources Clinical Interviewing, by Sommers-Flanagan and Sommers-Flanagan (note 1: I know it's expensive, but older versions may be cheaper; note 2: this is an Amazon Associates link). Tobii Dynavox (the AAC tech that was discussed in the show). Looking for a pod-based CEU on this topic? Check out: Session 194, Inside JABA 12: Cultural Responsiveness in Applied Behavior Analysis. Sponsor Shoutouts! Frontera. Consider taking a demo of Frontera's Assessment Builder and see how the ethical application of AI technologies can help you serve clients and save you time! Your first assessment report is free. And if you use code BOP25 you'll get an additional five assessments for just $100. So head to fronterahealth.com to check it out! Our newest sponsor: MindBodyBehavior's Certified Health Coach Program. If you're a BCBA looking to use your ABA skills to help people live healthier lifestyles, learn how to do it the right way, with expert instruction, mentoring, and guidance from Sarah Burby. Click here to learn more! HRIC Recruting. Cut out the middleman and speak directly with Barbara Voss, who's been placing BCBAs in great jobs all across the US for 15 years. Behavior University. Their mission is to provide university quality professional development for the busy Behavior Analyst. Learn about their CEU offerings, including their 8-hour Supervision Course, as well as their RBT offerings over at behavioruniversity.com/observations. Don't forget to use the coupon code, PODCAST to save at checkout!